Pembrolizumab Combo Extends Chemotherapy Benefit in Pancreatic Cancer
August 12th 2020Positive data from the phase IIa COMBAT clinical trial indicate that CXCR4 and PD-1 blockade with the combination of pembrolizumab and BL-8040 can improved upon the benefit of chemotherapy as treatment of pancreatic ductal adenocarcinoma.
Frontline Atezolizumab Plus Paclitaxel Misses Primary End Point in TNBC Trial
August 7th 2020The phase 3 IMpassion131 trial investigating atezolizumab plus paclitaxel versus placebo plus paclitaxel did not its primary end point of progression-free survival and was not statistically significant in the first line for patients with metastatic triple-negative breast cancer who had PD-L1-positive disease.
Dendritic Cell Vaccine Shows Long-Term Survival Benefit in High-Risk Melanoma
August 6th 2020The final data of a personalized tumor lysate, particle-loaded, dendritic cell vaccine demonstrated that patients with stage III or IV melanoma with high-risk of recurrence after complete surgical resection had better survival benefit and disease-free survival rate with the vaccine over placebo, according to a press release from Elios Therapeutics.
Single-Dose Netupitant/Palonosetron Bests 3-Day Aprepitant-Based Regimen to Prevent CINV
August 2nd 2020A single-dose combination of netupitant/palonosetron demonstrated better efficacy compared with a 3-day aprepitant-based regimen, according to results of a pooled analysis of multiple phase 2/3 studies investigating the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.
FDA Approves HPV Test With Extended Genotyping Capabilities
July 24th 2020The expanded version of the BD Onclarity HPV Assay received approval for a pre-market approval supplement from the FDA, making it the only assay approved right now that individually identifies and reports human papillomavirus genotypes 31, 51, 52, 33/58, 35/39/68, and 56/59/66, as well as the standard 16,18, and 45.
Study Shows Disparities, Effects of Treatment for Patients With Cancer and COVID-19
July 23rd 2020Data from a treatment utilization study revealed racial disparities in treatments as well as the effects and clinical outcomes of treatments such as remdesivir and dexamethasone in patients with cancer who were diagnosed with coronavirus disease 2019.
Pembrolizumab Shows Long-Term Benefit in Advanced Melanoma Subgroups
July 17th 2020A retrospective 10-year analysis of 3 randomized clinical trials explored the question of whether BRAF V600E/K mutations or previous use of a BRAF inhibitor with or without a MEK inhibitor in patients with metastatic disease impacted patient response to pembrolizumab.
Researchers Release Alternative Treatment Strategies During COVID-19 for NSCLC
July 16th 2020A nationwide group of clinical investigators teamed up to explore options on how to manage patients with locally advanced non-small cell lung cancer in a multidisciplinary setting during the ongoing pandemic of coronavirus disease 2019.
T-DM1 Shows Activity in HER2+ Metastatic Breast Cancer and Brain Metastases
July 11th 2020An exploratory analysis of trastuzumab emtansine demonstrated activity and tolerability in patients with HER2-positive locally advanced or metastatic breast cancer who have brain metastases participating in the prospective KAMILLA trial.
HEPANOVA Trial Update: Final Patient With HCC Enrolled to Receive TTFields/Sorafenib
July 9th 2020The last patient with advanced hepatocellular carcinoma was enrolled on the phase 2 HEPANOVA trial, which is investigating the combination of Tumor Treating Fields and sorafenib. The combination showed safety and tolerability for patients in an interim analysis.
Annamycin Demonstrates Efficacy for Lung Metastases in Preclinical Data
June 25th 2020"In the case of sarcomas treated with the current standard of care, doxorubicin, tumors may be initially responsive in their primary location, but become unresponsive after metastasis to the lungs, which eventually becomes the most likely cause of patients' death."
RAS/MAPK Pathway Mutations Show Association With Adverse Survival Outcomes in Myelofibrosis
June 19th 2020“RASMT associated with adverse phenotypic features were concluded to be an independent predictor of inferior overall survival and were associated with a higher cumulative incidence of leukemic transformation."
AON Announces Forthcoming Collaboration with Sarah Cannon to Expand Cancer Research
June 17th 2020“Community-based clinical trials come with many benefits. They enable patients to be matched with potentially life-saving research while staying within the comfort and familiarity of their local oncologist’s office.”
Clinical Activity Shown with Poziotinib in NSCLC and EGFR exon 20
June 4th 2020In a subgroup analysis of cohort 1 of the phase 2 ZENITH20 study, patients with previously treated non-small cell lung cancer and EGFR exon 20 insertions demonstrated clinical activity when receiving poziotinib, including those with central nervous system metastatic disease, which was not impacted by prior lines of therapy.
Key Efficacy End Points Upheld at 3 Years for Cemiplimab in CSCC
May 31st 2020“The data demonstrated deepening clinical responses with cemiplimab over time. Furthermore, duration of response and overall survival [OS] are considerably longer with cemiplimab than what has previously been recorded with other agents.”
First-in-Human Study Shows Favorable Activity With CC-92480 in Relapsed/Refractory Myeloma
May 30th 2020Favorable activity and safety findings were demonstrated with the combination of CC-92480 plus dexamethasone as treatment of patients with heavily pretreated relapsed or refractory multiple myeloma in an ongoing study, according to a presentation from the 2020 American Society of Clinical Oncology Virtual Scientific Program.
Molecular Drivers of Cancer to Be Focus of Discussions at Breast Cancer Conferences
April 16th 2020As the breast cancer setting quickly changes with each advancement, physicians who care for these patients will need to know how to apply these emerging treatments to the standards of care in their practice.
Before Starting Targeted Therapy for Prostate Cancer, Determine Cardiovascular Risk
March 21st 2020Elderly patients with advanced prostate cancer should be evaluated for preexisting cardiovascular diseases before taking oral androgen signaling inhibitors by a multidisciplinary team, includ­ing a cardiologist, according to a recent retro­spective study. Investigators at Thomas Jeffer­son University in Philadelphia, Pennsylvania, demonstrated that after receiving abiraterone acetate or enzalutamide, these patients had higher rates of short-term mortality than similar patients without CVDs.
Challenges for Clinical Trials and Treating Patients With Cancer in Light of the Coronavirus
March 20th 2020In an interview with Targeted Oncology, Randall A. Oyer, MD, discussed how his institution is handling the pandemic while still accommodating patients who are already on clinical trials and making sure everyone stays safe.